NRC Health (NRC): EBITDA
$30.21M
Year ended 2025-12-31
$23.37M
Trailing 12 months to 2026-06-30
-0.1%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.21M | -26.7% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $41.22M | -10.3% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $45.94M | n/a | 2026-03-05, From 2023-01-01 |
| No annual figure between 2019-12-31 and 2023-12-31. | |||
| 2019-12-31 | $48.57M | +19.2% | 2022-03-04, From 2019-01-01 |
| 2018-12-31 | $40.74M | +5.0% | 2021-03-05, From 2018-01-01 |
| 2017-12-31 | $38.80M | +9.6% | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | $35.42M | +15.9% | 2019-03-08, From 2016-01-01 |
| 2015-12-31 | $30.56M | -4.8% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $32.10M | +12.5% | 2017-03-03, From 2014-01-01 |
| 2013-12-31 | $28.54M | +4.1% | 2016-03-04, From 2013-01-01 |
| 2012-12-31 | $27.42M | +15.2% | 2015-03-04, From 2012-01-01 |
| 2011-12-31 | $23.80M | +28.2% | 2014-03-04, From 2011-01-01 |
| 2010-12-31 | $18.56M | +5.9% | 2013-03-01, From 2010-01-01 |
| 2009-12-31 | $17.53M | n/a | 2012-03-01, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| NRC Health (NRC) | 2025-12-31 | $30.21M | -26.7% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$47.56M | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$47.22M | n/m |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | -$9.73M | n/m |
| bioAffinity Technologies, Inc. (BIAF) | 2025-12-31 | -$10.07M | n/m |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $428.47M | -27.3% |
| Incyte Corp (INCY) | 2025-12-31 | $1.61B | +967.7% |
| Absci Corp (ABSI) | 2025-12-31 | -$108.58M | n/m |
| Icon PLC (ICLR) | 2025-12-31 | $825.84M | -45.7% |
Compare NRC, MXCT, OABI, FOXO side by side · Screen every company in Services-Commercial Physical & Biological Research ↗